Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP, Global Operations | May 02, 2025 | May 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date May 02, 2025 · Filed May 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,705 |
Ending reported balance
After 2025-05-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-05-02 · Exercise / conversion · Acquired 4,204 · Balance 25,195 F1: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2025-05-02 · Tax withholding · Disposed 1,918 · Balance 23,277 Row 3 · 2025-05-05 · Sale · Disposed 4,572 · Balance 18,705 F2: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-05-02 | Direct | 4,204 |
Reported balance
After 2025-05-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-02 · Exercise / conversion · Disposed 4,204 · Balance 4,204 F1: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
F3: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2024 Filed Feb 21, 2024 02:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002579 · doc4.xml · derivative · entry 7 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,546 Underlying: Common Stock · 1,273 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 581 | $65.82 | $38,241.42 |
DisclosureSEC source: 0001225208-24-002579 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,178 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002579 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002308 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,345 Underlying: Common Stock · 2,115 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 965 | $65.95 | $63,641.75 |
DisclosureSEC source: 0001225208-24-002308 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,486 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002308 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 18,254 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002048 · doc4.xml · derivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,254 Underlying: Common Stock · 18,254 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 6,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002048 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,924 Underlying: Common Stock · 6,924 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001782 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,336 Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001782 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,808 F1 · kind: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 01:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-000110 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,848 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. F1 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. F1 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 01:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,729 | $57.81 | $215,573.49 |
DisclosureSEC source: 0001225208-24-000110 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,808 Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 01:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-000110 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005386 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,611 Underlying: Common Stock · 4,203 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,917 | $52.90 | $101,409.30 |
DisclosureSEC source: 0001225208-23-005386 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,689 Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005386 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 20:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,000 | $50.00 | $200,000.00 |
DisclosureSEC source: 0001225208-23-004334 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,403 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 10, 2023. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002535 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,091 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 498 | $46.23 | $23,022.54 |
DisclosureSEC source: 0001225208-23-002535 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,403 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002535 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · derivative · entry 9 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,186 Underlying: Common Stock · 1,186 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 541 | $46.54 | $25,178.14 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 6 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,810 Read SEC document |
| February 18, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 5 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · derivative · entry 8 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,500 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 685 | $46.54 | $31,879.90 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 4 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,165 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · derivative · entry 7 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,819 Underlying: Common Stock · 1,272 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 581 | $46.48 | $27,004.88 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,350 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002381 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002156 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 548 | $47.29 | $25,914.92 |
DisclosureSEC source: 0001225208-23-002156 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,659 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002156 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 22,014 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002040 · doc4.xml · derivative · entry 4 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,014 Underlying: Common Stock · 22,014 shares Expires 2033-02-14 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 8,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002040 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,460 Underlying: Common Stock · 8,460 shares Expires 2027-02-14 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 4,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002040 · doc4.xml · derivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,469 Underlying: Common Stock · 4,469 shares Expires 2024-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · balance_after: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. Read SEC document |
| February 06, 2023 Filed Feb 15, 2023 22:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 4,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002040 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,007 Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 4,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-000053 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,202 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. F1 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. F1 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,463 | $46.27 | $67,693.01 |
DisclosureSEC source: 0001225208-23-000053 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,786 Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-000053 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. Read SEC document |
| May 02, 2022 Filed Sep 1, 2022 20:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 16,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-009904 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,814 Underlying: Common Stock · 16,814 shares Expires 2026-05-02 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's committment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003869 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,222 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 374 | $44.17 | $16,519.58 |
DisclosureSEC source: 0001225208-22-003869 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,047 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003869 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003301 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,848 Underlying: Common Stock · 7,848 shares Expires 2023-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · balance_after: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003089 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,091 Underlying: Common Stock · 1,090 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 334 | $42.55 | $14,211.70 |
DisclosureSEC source: 0001225208-22-003089 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,199 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003089 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002934 · doc4.xml · derivative · entry 6 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,372 Underlying: Common Stock · 1,186 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 363 | $42.55 | $15,445.65 |
DisclosureSEC source: 0001225208-22-002934 · doc4.xml · nonDerivative · entry 4 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,443 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002934 · doc4.xml · nonDerivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.